Figure 6 2.6 PCD and the immune microenvironment of COPD As demonstrated by the various types of PCD described above, the remodeling of the immune microenvironment in COPD is not driven by a single mode of cell death, but rather the result of the superimposed effects of multiple PCDs across different cell types and disease stages: at the level of cell lineage, structural cells (airway/alveolar epithelium, vascular endothelium, smooth muscle, fibroblasts) primarily undergo apoptosis, necroptosis, ferroptosis, and cuproptosis, which together determine barrier integrity, the degree of airway remodeling, and the extent of alveolar destruction
Furthermore, GHK-Cu has demonstrated neuroprotective properties and can promote the growth of new neurites, potentially enhancing cognitive function and protecting against age-related decline
Moreover, GLP-1 receptors have been identified on several immune cells including ILC2 cells, regulatory T cells, eosinophils, neutrophils, and macrophages
However, our medical experts expect that Microdosing Tirzepatide may sustain many of the same benefits that low doses of Tirzepatide-based injectable medications have shown individually in the studies cited below
Glucagon-like peptide-1 (GLP-1) is a hormone and neuropeptide produced in the intestine and brain